TBPH Q3 2018 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+200.3% YoY

Gross Profit

$12M94.5% margin

Operating Income

-$62M-486.4% margin

Net Income

-$59M-462.9% margin

EPS (Diluted)

$-1.10

QoQ Revenue Growth

-45.3%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$51M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$371M

Total Liabilities

$384M

Stockholders' Equity

-$13M

Cash & Equivalents

$101M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$4M	+200.3%
Gross Profit	$12M	$3M	+268.8%
Operating Income	-$62M	-$57M	-9.6%
Net Income	-$59M	-$67M	+11.1%

Revenue Segments

Collaborative Arrangement Revenue

$9M70%

Product

$4M30%